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Abstract 
 
Parkinson’s disease is the second most common neurodegenerative disorder in the aging 
population. It is associated with progressive loss of nigrostriatal dopaminergic neurons. 
Parkinsonism is a clinical syndrome that consists of motor and non-motor symptoms. It has been 
well described that many if not all of these deficits are associated with abnormalities related to 
the neurotransmitter dopamine. This review is intended for primary care physicians who often 
establish the diagnosis and initiate Parkinson’s treatments. One challenge faced by the primary 
care physician is to decide the appropriate medication and starting dose. Often medications are 
used at very low doses or incorrect dosing schedules.  This review aims to summarize these 
medications, their potential side effects and the rationale for medication choices. 
 
Keywords 
 
Parkinson's medical 
 
Introduction  
Parkinson’s disease is neurodegenerative disorder. It is the second most common 
neurodegenerative disorder in the aging population.1 Parkinson’s disease is associated with 
progressive loss of nigrostriatal dopaminergic neurons.2 Parkinsonism is a clinical syndrome that 
consists of motor symptoms such as bradykinesia (slowness of movement), akinesia (lack of 
movement), hypokinesia (smallness of movement), tremor, rigidity, and postural disturbance, 
and non-motor symptoms such as pain, sleep disturbance, apathy, depression, dementia, 
orthostatic hypotension and constipation.2 The symptoms of Parkinson’s start on one side of the 
body and then spread to the other side. Cognitive impairment in Parkinson's disease is common 
and disabling. The prevalence of dementia is 25%; in patients who live more than twenty years 
with motor symptoms, the prevalence rises to 83%.3 It has been well described that many if not 
all of these deficits are associated with abnormalities related to the neurotransmitter dopamine. 
The diagnosis of Parkinson’s disease is based mainly on clinical assessments.1 Parkinson’s 
disease is diagnosed by the presence of bradykinesia and presence of rigidity, resting tremor or 
postural instability. 
UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria 
• Bradykinesia 
At least one of the following 
• Muscular rigidity 
• 4-6Hz rest tremor 
• Postural instability not caused by primary visual, vestibular, cerebellar or 
proprioceptive dysfunction 
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This review is intended for primary care physicians who often establish the diagnosis and initiate 
treatments. Over the last fifty years since the advent of Levodopa, there have been multiple 
medications which have become available. One of the challenges faced by the primary care 
physician is to decide the appropriate medication and starting dose. Often medications are used 
at very low doses or incorrect dosing schedules. Obtaining an appointment with a movement 
disorders specialist in the United States often takes two to eight months which translates into 
inadequate symptom control for many patients.4 This review aims to summarize these 
medications, their potential side effects and the rationale for medication choices. 
 
Methods 
 
This research content is derived from a PubMed search of key words “Parkinson’s” “medical 
treatment” and “non-surgical treatment” including citations from 1946 to January 1, 2017. The 
search was limited to English language articles only. This narrow range of keywords was used in 
an attempt to capture only articles relevant to the medical treatment of Parkinson’s disease. The 
PubMed search strategy was developed in conjunction with the Director of Health Science 
Library at the Health Science Library- Joan C. Edwards School of Medicine, a librarian 
knowledgeable in systematic review methodology and reviewed by the investigators. The 
PubMed search included a focused search for “Parkinson’s non-surgical treatment” without 
restriction to preclinical studies or age groups, followed by an expanded search for “Parkinson’s 
medical treatment”. No language or study design limits were applied. Titles and abstracts from 
the preliminary search were vetted to identify potentially pertinent articles. First and second 
authors individually assessed the full-text of these publications for eligibility and any 
disagreements about inclusion were agreed through discussion and consensus. 
 
 
Table 1: Classification of nonsurgical Parkinson's Disease treatments 
Class Medication 
Supplemental Dopamine Carbidopa-Levodopa IR and CR 
 Rytary 
 Stalevo (CD-LD + Entacapone) 
Anticholinergics Benztropine 
 Trihexyphenidyl 
glutamateric N-methyl-D-aspartate 
(NMDA) antagonist + dopamine release 
+ decreased uptake 
Amantadine 
Dopamine agonists Ropinirole 
 Pramipexole 
 Rotigotine 
 Apomorphine 
Monoamine Oxidase (MAO) inhibitors Rasagiline 
 Selegiline 
COMT inhibitors Entacapone 
 Tolcapone 
 
Carbidopa-Levodopa 
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 Currently, levodopa (LD) is the most potent medication for treatment of motor symptoms in 
Parkinson’s disease. In 1960 Ehringer and Hornykiewicz discovered the striatal dopamine 
depletion in Parkinson's disease. With the knowledge that levodopa was the natural precursor to 
dopamine, they suggested human trials in Parkinson's disease patients.5 It is available in 
immediate release, controlled release and oral disintegrating forms.6 Levodopa has a relatively 
short half-life (∼1.5 hours), and is quickly and extensively metabolized in plasma.7 Levodopa is 
actively absorbed, mainly in the proximal small intestine and is rapidly metabolized by aromatic 
L‐amino acid decarboxylase (AADC). Therefore, levodopa products are formulated with an 
AADC inhibitor, commonly carbidopa (CD), to prevent peripheral metabolism and increase the 
fraction of levodopa transported to the brain for conversion to dopamine.8 Combining carbidopa 
and levodopa improves tolerability by reducing nausea and other adverse effects from peripheral 
decarboxylation, making oral use of levodopa practical. The ratio of carbidopa: levodopa should 
be ideally 1:4 for better CNS penetration. Levodopa is best absorbed if taken separate from 
proteins since proteins can interfere with absorption. Ideally, a gap of forty five to sixty minutes 
is recommended. Clinicians should initiate levodopa treatment with low doses and proceed by 
small increments.9 Typically, the 25/100 formulation is initiated at a dose of one tab three to four 
times daily. Due to its short half-life, it is ideally taken at four hour intervals. Long term use of 
high dose of carbidopa-levodopa can cause dyskinesia, and motor fluctuations. Patients with 
Parkinson’s disease can also develop dopamine dysregulation syndrome after many years of 
use.9 Carbidopa-levodopa is the preferred drug especially in the older population since it is less 
likely to cause side effects compared to other drugs. Most common side effects are nausea, 
dizziness, drowsiness, orthostasis, hallucinations and confusion.10 
 
Controlled release (CR) formulation, which uses a degradable polymer matrix to slow the release 
of LD, was developed as an alternative to the Immediate Release (IR) form. It has not shown a 
significant reduction in “off” time as compared to IR formulation. Absorption is delayed and its 
effect is not as predictable. CR is mainly used at night time to help with early morning off 
periods. Some physicians do use it along with IR, though that does increase the complexity of 
dosing for patients. 
 
Anticholinergics: Benztropine, Trihexyphenidyl 
 
In the early 1960s, it was theorized by André Barbeau that the dopaminergic deficit would lead 
to an increase in striatal cholinergic activity, contributing to tremor and other symptoms.6 
Anticholinergics side effects include memory loss, confusion, hallucinations, constipation, 
urinary retention, dry mouth, dry eyes, and blurred vision.6 There is strong evidence that the 
main autonomic adverse effects of cholinergic drugs are mediated by the activation of peripheral 
M2 and M3 receptors, while cognitive effects may be related to M1 receptor activation.6 
 
1. Benztropine 
 
Benztropine’s effect is believed to be most notable for tremor 6. Benztropine is initiated at 0.5 
mg twice daily and increased by 0.5 to 1.0 mg every three to four days as necessary to maximum 
of 3 to 4 mg per day.11 
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2. Trihexyphenidyl 
 
Like benztropine, trihexyphenidyl effect is believed to be most notable for 
tremor.6 Trihexyphenidyl is generally initiated at 2 mg by mouth three times a day and increased 
to a maximum of 5 mg three times a day.11 
 
Amantadine 
 
Amantadine was developed as an antiviral agent.  It was used widely in nursing home 
populations, and Schwab noted its unexpected benefit on tremor, balance, and akinesia in both 
Parkinson's disease and postencephalitic parkinsonian patients.5 Amantadine is a glutamateric N-
methyl-D-aspartate (NMDA) antagonist and has been postulated to increase dopamine release, 
decrease the reuptake of dopamine and stimulate dopamine receptors.11 Amantadine is often used 
in early Parkinson disease for tremor control and for treatment of dyskinesias and fatigue. It is 
the only drug that is intrinsically antidyskinetic and improves Parkinson symptoms. Side effects 
of amantadine include leg swelling, livedo reticularis, and neuropsychiatric and anticholinergic 
effects.12 Amantadine is generally initiated at 100 mg/day and increased up to 300 mg/day as 
necessary.11 Patients with renal failure will need dose adjustments. 
 
Dopamine agonists 
 
Pramipexole, ropinirole, rotigotine and apomorphine are dopamine agonists. Pramipexole and 
ropinirole immediate-release (IR) are rapidly absorbed and reach a maximum concentration 
between one and two hours after administration.13 Pramipexole and ropinirole are available in 
extended release (ER) forms which might be better tolerated. Their central dopaminergic adverse 
effects include hallucinations, psychosis, dyskinesias, dizziness, drowsiness and peripheral 
effects (nausea, orthostatic hypotension, edema).13 In early Parkinson’s disease pramipexole and 
ropinirole significantly improve disability scales, delay time to dyskinesia and allow a later 
introduction of levodopa. Dopamine agonists are preferred as initial therapy in younger patients 
but might be more likely to cause side effects in the elderly. They are more likely to cause 
impulsive-compulsive behaviors such as gambling, shopping, hypersexuality, hoarding etc. as 
compared to CD-LD. 
 
1. Pramipexole 
 
Pramipexole is a full intrinsic dopamine agonist with a nonergot structure. It is a potent D2 
agonist with maximum affinity for the D3 subtype.
13 Pramipexole is available in 0.125 mg, 0.25 
mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg forms and is gradually titrated to target range of 1.5-4.5 
mg/day to be administered three times daily.13 Pramipexole tablets are taken orally, with or 
without food. Pramipexole has a six hour half-life 6.6 In late Parkinson’s disease, Pramipexole 
reduced total ‘off’-time.13 
 
2. Ropinirole 
 
Ropinirole, a potent dopamine agonist, binds to both peripheral and central receptors and has 
maximum affinity for the D3 sub- type.
13 It is dosed at 0.25, 0.5, 1, 2, and 5 mg. Ropinirole has 
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an eight hour half-life.6 Dose up-titration is also performed on a weekly basis until reaching 8 mg 
daily in the first month.13 Typical daily dose is 8 to24 mg. 
3. Rotigotine 
 
Rotigotine is applied trans-dermally. Dopamine agonists are often applied as an initial treatment 
in Parkinson's disease due to their low potential to develop dyskinesia.14 Nowadays, mainly 
twenty four hour prolonged release formulations of dopamine agonists are in use and have shown 
significant reduction of “off” time.14 Rotigotine has a high affinity for D3 receptors as well as an 
agonist effect on serotonin receptors and an antagonist effect on adrenergic receptors.
13 
Rotigotine patches are dosed at 1, 2, 3, 4, 6, and 8 mg.13 
 
4. Apomorphine 
 
Apomorphine (APO) is a D1/D2 receptor dopamine agonist with a short half-life of nearly forty 
five minutes. Apomorphine is used to assess Parkinson's disease patients’ responsiveness to 
levodopa or a dopamine agonist, as a rescue therapy for sudden off-periods. Apomorphine is also 
available in the UK as a continuous subcutaneous infusion for treatment of motor.15 The drug is 
rapidly absorbed after subcutaneous injection, and has a half-life of thirty to sixty minutes. 
Clinical improvements start within twenty minutes of administration.6 Apomorphine injections 
via pen administration are reasonable for a rapid relieve of a sudden “off” fluctuation during the 
daytime and nighttime and to conquer end-of-dose biphasic dyskinesia.14 Double-blind studies 
with injection doses of 1-5 mg have demonstrated that onset of clinical benefit typically occurs 
within ten minutes.16 One of the main side effects of apomorphine are skin reactions located at 
the injection side resulting in a formation of small nodules. Other side effects include increased 
daytime sleepiness, nausea, dizziness, renal impairment and orthostatic hypotension. In order to 
prevent nausea, the patient is pre-treated with trimethobenzamide. Neuropsychiatric changes like 
hallucinations and psychosis are rare but can be observed with high dosages of apomorphine.14 
Apomorphine treatment is restricted only to patients with advanced Parkinson's disease due to 
the high cost of the drug. The long term use of APO is less likely to induce the impulsive and 
compulsive behaviors characterized by hypersexuality and gambling.15 
 
Selective MAO-Inhibitors  
 
Monoamine oxidase is a widely distributed mitochondrial enzyme.  It catalyzes the oxidative 
deamination of a variety of monoamines, both endogenous and exogenous, and has major roles 
in metabolizing released neurotransmitters, and in detoxification of a large variety of endogenous 
and exogenous amines.17 Symptoms of Parkinson's disease are improved with dopamine 
antagonist (DA) replacement therapies such as DA receptor agonists and LD. Over time, 
however, the benefit of these drugs fluctuates and patients begin to experience loss of benefit 
with each dose of LD (wearing–off) and involuntary dyskinesia. In addition some parkinsonian 
symptoms including disturbances of gait and tremor may be resistant to dopaminergic therapy.17 
Inhibition of monoamine oxidase B (MAO-B) may conserve the depleted synaptic levels of DA, 
and delay the need for treatment with levodopa in patients with early-stage Parkinson's disease. 
In patients with advanced-stage Parkinson's disease who experience fluctuations in response to 
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levodopa, MAO-B inhibition potentiates and prolongs the effect of levodopa and permits use of a 
lower dose.17 Selegiline and rasagiline are approved as adjunct treatments to levodopa.11 
 
1. Selegiline 
 
In 1989, Tetrud and Langston published a clinical study based on the discovery that selegiline 
blocked the development of MPTP-induced parkinsonism in laboratory animals.17 Selegiline 
undergoes first-pass metabolism to R(−)amphetamine and R(−)methamphetamine, which have 
the potential to cause cardiovascular and CNS adverse effects.17 Selegiline is dosed at 5 to 10 
mg/day.18 In general, selegiline is well tolerated. Side effects/adverse effects like nausea, 
vomiting, sleeplessness, dry mouth, orthostatic hypotension and dyskinesias have all been 
observed in the range of 2–5% of Parkinson's disease patients. Other side effects like headaches, 
palpitations, dyspnea, confusion, edema, micturition dysfunction, loss of appetite and anxiety 
have an incidence below 2%. 
 
Rasagiline 
 
Rasagiline is a potent, selective, irreversible inhibitor of MAO-B and in contrast to selegiline has 
no amphetamine-like metabolites.17 Rasagiline shows good antiparkinsonian and motor 
restoration activity as well as neuroprotection properties.17 Rasagiline is dosed at 1 mg/day.18 
Side effects of rasagiline include nausea, vomiting, orthostatic hypotension, somnolence, 
hallucinations and dyskinesias.18 Because rasagiline inhibits MAO-B more potently than 
selegiline it has the advantage of once-daily dosing.19 Rasagiline has demonstrated 
neuroprotective properties in a host of in vitro and in vivo studies. The ADAGIO (Attenuation of 
Disease Progression with Azilect Given Once-daily) trial suggested potential disease-modifying 
effects for rasagiline at 1 mg/day, though no such benefit was observed at 2 mg/day doses. The 
study also showed that it is safe to use with selective serotonin reuptake inhibitor. Patients with 
Parkinson’s disease often have depression or anxiety, both of which can impair quality of life.19 
Rasagiline at a dose of 1 mg/day slowed the rate of Unified Parkinson's disease Rating Scale 
(UPDRS) progression, improved symptoms from baseline and was shown to be non-inferior.19 
 
COMT Inhibitors 
 
Catechol-O-methyltransferase (COMT) is an enzyme that degrades catecholamines like 
dopamine. Entacapone and tolcapone are COMT inhibitors. They are another adjunctive option 
for the treatment of advanced Parkinson’s disease. The enzyme COMT breaks down levodopa; 
therefore, the addition of a COMT inhibitor allows more levodopa to reach the brain.11 
Entacapone acts peripherally while tolcapone acts peripherally and centrally. 
 
Entacapone 
 
Entacapone is effective in reducing “off” time at an average of 0.7 to 1.2 hours per day and 
should be offered to patients with motor fluctuations. Entacapone is available in 200 mg tablets. 
One tablet is given with each dose of levodopa, not to exceed a total daily dose of 1600 mg.11 
The most common adverse effects of entacapone include dyskinesia, nausea, diarrhea, and urine 
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discoloration.20 Stalevo is a formulation that contains combination of carbidopa, levodopa and 
entacapone. 
 
Tolcapone 
 
Tolcapone has been determined to be probably effective in the treatment of “off” time with an 
average daily reduction in “off” time of 0.9 to 1.8 hours.11 Tolcapone is initiated at 100 mg three 
times daily and increased to 200 mg three times daily if necessary.11 Tolcapone arrived on the 
market in 1997/1998 and its side effects include elevated liver transaminases and 
hepatotoxicity.21 
 
Rytary 
 
Levodopa is the most effective oral pharmacotherapy developed to date and is typically 
administered in combination with a dopa-decarboxylase inhibitor such as carbidopa. Rytary is an 
extended-release (ER) formulation of carbidopa and levodopa in a 1:4 ratio. It was designed to 
rapidly achieve therapeutic plasma levodopa concentrations and maintain them for a prolonged 
duration to allow a dosing interval of approximately 6 hours in both early and advanced 
disease.22 The most commonly reported adverse events with Rytary included nausea, dizziness, 
and headache.23 In early Parkinson's disease, the most frequently reported adverse effects, nausea 
and insomnia, are commonly reported for dopaminergic drugs. In advanced Parkinson's disease, 
the most frequently reported adverse effects, dyskinesia and fall, are commonly associated with 
Parkinson's disease therapies and/or Parkinson's disease progression.22 The ADVANCE-PD 
study showed that patients can be safely switched from standard immediate release (IR) CD-LD 
to rytary with reduced “off”, decreased fluctuations, and better quality of life. ASCEND- PD 
study reported that rytary significantly decreased “off” time and increased “on” time without 
troublesome dyskinesia, as compared to stalevo (CD-LD-entacapone).7 Immediate release 
carbidopa-levodopa has a short half-life. Over time, there is shortening of clinical response and 
higher more frequent dosing is needed. It is believed that the short interval dosing causes post 
synaptic changes in the striatum. These changes, as well as progression of the disease, lead to 
motor fluctuations and dyskinesias. Patients who are experiencing motor fluctuations are 
probably the best candidates for rytary.7 In order to transition a patient from regular 
carbidopa/levodopa to rytary, the total daily levodopa dose is roughly doubled and divided into 
three or four doses. 
 
Management of motor symptoms in Parkinson’s disease is very complex. Medications with 
different mechanisms of action are often used in conjunction. Contrary to general principles, 
Parkinson’s disease is a condition in which we often use polypharmacy to achieve better 
outcomes. To summarize, younger patients (<65-70 years) benefit from dopamine agonists or 
MAO-B inhibitors to begin with as this delays use of levodopa and the subsequent onset of 
motor fluctuations. However, younger patients who do not respond adequately to other agents 
should be started on levodopa. Older patients tend to tolerate levodopa better than other agents 
and it should, therefore, be the drug of choice. Amantadine and anticholinergics are particularly 
beneficial in treating tremor. The landscape of medical therapies for motor symptoms in 
Parkinson’s disease continues to expand. Some of the ones in the pipeline include the accordian 
pill, inhaled levodopa, tozadenant, sublingual apomorphine. Appropriate choice of medications 
will provide greater symptom relief for patients prior to seeing a specialist.  
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